Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy
Related Experiment Video
Updated: Jan 27, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Emre Akar1, Mehmet Haluk Yücel1, Tunahan Şahin1
1Department of Internal Medicine, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Faculty of Medicine, Bakirkoy, Istanbul, Turkey.
Background:
Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis.
Case Report:
A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib. Sixteen months after sunitinib inception, liver enzymes were elevated and viral hepatitis reactivation was detected as hepatitis delta virus infection in the HBsAg-positive patient.
Conclusion:
Cancer patients should be screened for viral hepatitis prior to immunosuppressive therapy or chemotherapy.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Receiver Operating Characteristic Plot
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Cross-reactivity
Reactivity of Enols